Author

Francisco Figueiredo

Universidade do PortoORCID 0000-0001-5933-9875Unclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Francisco Figueiredo1 paper

Biology Disciplines

Click to filter author papers

Biophysics· 1 Neuroscience· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:C. elegans· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

Alexandra SilvaiD· 2 shared Andreia Teixeira‐CastroiD· 2 shared Daniela Vilasboas‐CamposiD· 2 shared Patrı́cia MacieliD· 2 shared Pedro Miguel MartinsiD· 2 shared Sandra Macedo‐RibeiroiD· 2 shared Ana Luı́sa CarvalhoiD· 1 shared Andreia Neves‐CarvalhoiD· 1 shared

Activity by Year

2023-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiophysics

Alexandra SilvaORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

BiophysicsAdvanced SciencePeer-reviewedNov 26, 2025

Allosteric Modulation of Pathological Ataxin-3 Aggregation: A Path to Spinocerebellar Ataxia Type-3 Therapies

Alexandra Silva, Sara Duarte‐Silva, Pedro Miguel Martins…·Sandra Macedo‐Ribeiro

This study shows that CLR01, a supramolecular tweezer, reduces Atx3 aggregation by binding to a specific site, delaying fibril formation and improving symptoms in SCA3 models.

DOI 10.1002/advs.202502216

humanC. elegans

𝕏 PostBluesky

NeuroscienceBiomedicine & PharmacotherapyPeer-reviewedAug 5, 2023

Drug repurposing of dopaminergic drugs to inhibit Ataxin-3 aggregation

Francisco Figueiredo, Zsuzsa Sárkány, Alexandra Silva…·Sandra Macedo‐Ribeiro

This study identifies dopamine and catecholamines as inhibitors of Atx3 aggregation, suggesting potential use of dopaminergic drugs for MJD treatment.

10 citations

experimental assaydrug response / drug discovery

𝕏 PostBluesky